We discuss the preclinical evidence demonstrating the therapeutic potential of nAChR ligands in Alzheimer disease, Parkinson disease, schizophrenia spectrum disorders, and in autosomal dominant sleep-related hypermotor epilepsy. The gene discussed is CHRNA4; the disease is early-onset autosomal dominant Alzheimer disease.